Company intelligence / Profile preview

Chiroscience Group Plc

Cambridge, United Kingdompharmaceuticalonline.com ↗

Ownership: Private
Employees: ~400
Development stage: Commercial

Overview

Chiroscience developed the anesthetic Chirocaine (levobupivacaine), which was approved before the company’s acquisition. It also discovered Romosozumab for osteoporosis. At merger with Celltech in 1999, it had a broad pipeline including three products in advanced trials and eight more at clinical or preclinical stages. The company was recognized as an innovator in chiral chemistry.

Therapeutic areas: OtherEndocrinology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

Chirocaine

Commercial

Indications: Local anesthesia

Beyond the preview

Go deeper on Chiroscience Group Plc.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chiroscience Group Plc.

Explore the full profile